Sanfilipo M, Wolkin A, Angrist B, van Kammen D P, Duncan E, Wieland S, Cooper T B, Peselow E D, Rotrosen J
Department of Psychiatry, New York Veterans Affairs Medical Center, 10010, USA.
Psychopharmacology (Berl). 1996 Jan;123(2):211-4. doi: 10.1007/BF02246180.
The purpose of this study was to assess further the effect of amphetamine on negative symptoms of schizophrenia. Thirty-seven schizophrenic males meeting DSM-III criteria were rated with the Brief Psychiatric Rating Scale, the Abrams and Taylor Scale, and the Abnormal Involuntary Movements Scale before and after double-blind administration of either amphetamine (n = 26) or placebo (n = 11). Our results indicated that amphetamine administration generally did not improve negative symptoms, even when accounting for changes in positive symptoms. However, greater baseline negative symptoms were associated with a modest diminution after amphetamine treatment. Therefore, amphetamine may modestly improve negative symptoms in those schizophrenics in whom this symptomatology is more severe.
本研究的目的是进一步评估苯丙胺对精神分裂症阴性症状的影响。37名符合DSM-III标准的男性精神分裂症患者在双盲服用苯丙胺(n = 26)或安慰剂(n = 11)之前和之后,使用简明精神病评定量表、艾布拉姆斯和泰勒量表以及异常不自主运动量表进行评分。我们的结果表明,即使考虑到阳性症状的变化,服用苯丙胺通常也不会改善阴性症状。然而,基线阴性症状较重者在接受苯丙胺治疗后症状有一定程度减轻。因此,苯丙胺可能会使那些阴性症状较为严重的精神分裂症患者的阴性症状得到一定程度的改善。